IMUC Earnings For Monday Preview
ImmunoCellular Therapeutics, Ltd. (TSL)
Background:ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors. The company is based in Woodland Hills, California.
Strong third-quarter earnings growth is expected by Wall Street before the market opens on November 24, 2014. The consensus mean is 15 cents a share, a gain of 1 cent (7.1%) from 14 cents during the corresponding quarter last year.
Estimates begin at 4 cents, and climb to the most promising per share estimate of 25 cents. With that said, let's take a look at non-official analysts are thinking.
The majority of analysts believe IMUC continues to offer a buying opportunity. 7 of the 12 analysts covering the company give a buy recommendation. Some (5) are taking a more cautious approach, and rate it a hold. As of the last update I have, none of the analysts are recommending selling. Investors haven't made progress this year. Shares in the company have fallen 31% from a year ago. The average analyst target price for IMUC is $18.31.